FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. - Wikidata - wikimedia - TriplyDB

FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.

FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.

http://www.wikidata.org/entity/Q34359341

about

The role of HGF/c-MET signaling pathway in lymphoma Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application.Clinical potential of gene mutations in lung cancer.Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening Bilateral breast adenocarcinomas with EML4-ALK fusion in a patient with multiple metastases successfully treated with crizotinib: is lung the primary site?Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.Pharmacokinetics of crizotinib in NSCLC patients.The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer.Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals.New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.Anaplastic lymphoma kinase: Role in cancer and therapy perspective.Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.Sufficiency of Single-Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib.Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.Emerging treatment for ALK-positive lung cancer.Surrogate endpoints for overall survival in lung cancer trials: a review.Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand.Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors.[Clinical Efficacy of Crizotinib in Treatment of Patients with Advanced NSCLC].Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies.Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors.EML4-ALK-positive lung adenocarcinoma presenting an unusual metastatic pattern in a 29-year-old woman who is alive and well in her third year follow up:A case report.Efficacy of crizotinib in ALK fusion variants.Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents.Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs.Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.Targeted therapy with apatinib in a patient with relapsed small cell lung cancer: A case report and literature review.Precision oncology: neither a silver bullet nor a dream.Screening for ALK abnormalities in central nervous system metastases of non-small-cell lung cancer.Single oral dose acute and subacute toxicity of a c-MET tyrosine kinase inhibitor and CDK 4/6 inhibitor combination drug therapy.Implications of KRAS mutations in acquired resistance to treatment in NSCLC.Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma.Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Non-Small Cell Lung Cancer.

P2860

Q28069836-D556124A-D8F6-4487-8A81-C2FA967722E8 Q33921813-059FC312-4A21-4286-B663-9EE5F93D4D63 Q34712645-D183BED7-F74F-4558-9A7E-687CE3C22A12 Q36316009-29F338A9-9A3C-4739-89C5-9E90837EDF99 Q36414458-4ECE7E9A-192A-484C-ABA0-28BCF1F248E0 Q37021294-18400E21-1751-46EE-83F5-AB4C28C84511 Q37162291-EA321FCB-32ED-45B5-B139-41DC5D89F65C Q38366828-5B555CCD-59C9-457D-A639-3E8F6D6D299A Q38388307-0D8677D7-B3D2-4924-BA55-F737AD5D7DC3 Q38528130-99EE2401-FB28-4114-9C84-F77858D92161 Q38537425-57C0C285-4858-4D08-A9F8-449EA1F31DA6 Q38576015-FF0FF78D-592E-44A9-8548-79C426159493 Q38623421-7A05AA4C-FC5B-410A-9B09-755885B11AA3 Q38644718-A3AC832E-4EBE-47DB-AB4C-FDBCD1A0FFEC Q38665438-01908A5C-94F3-4300-83B1-791A58655EA4 Q38670719-59C1C435-43EE-46B6-83BC-13DC69E8B441 Q38721743-E8FA98EB-A137-41EF-BBF2-98E9A15ABDB8 Q38748356-E135E346-D039-4A2B-B2AD-2200948F580C Q38819472-E198E24E-20BE-43D8-AEBD-AD0E6B45E905 Q38841987-87B79106-8BB7-4F87-A1BB-CA416E78CAA3 Q38880510-0B64EEFC-AB5E-4E20-A586-F5DDB072CFF3 Q38906188-18F5AFF0-F105-4A44-9DE0-A979DD05C1B5 Q38917830-37DBB5ED-442A-497A-A1D2-026205E0E99F Q39004424-09810FAC-6C3C-403A-BA8D-7BAEE0529972 Q40835693-5436D9F3-576A-4EAF-B3F1-9770FEBB4619 Q40996798-30EC9725-3936-4792-ABEC-A7884FECE3B4 Q41341776-F8D83F1C-B63C-41C2-90C0-44D6DCF9BB73 Q41492859-6D623725-1196-4B07-B826-63D5D36AB305 Q41764706-D3041540-DB41-4F6A-A7B1-D7F7E7B79B91 Q42373819-B402D634-A6DB-4790-95C0-E630FECD5177 Q43259078-DC5150F4-6FF9-4B52-B13A-05C232940143 Q45559181-BD590D04-A540-4AB8-AC1A-ABCF2FFC835A Q47640411-1DDA05CD-FF2A-4AFC-969E-F5D6C9A01E65 Q47737073-45DD116D-5941-4523-963D-9DD4ECCA44A4 Q48419474-2A7075D4-C9EF-4BC8-8D1E-D9B8C46B47B5 Q49335307-EBFDC15A-27DF-4333-93D3-7F38E5CE1423 Q49787333-F8D11E78-FCC2-4DB2-8368-B4060247207D Q49887930-D0B04CCA-6996-4211-B031-F4E6B2BACE64 Q50985091-06AEA4BF-C3D2-4689-BF32-A9FC61E928F6 Q53001245-222A47C0-9CB2-4C5A-AFFE-6A8578680B7B

P2860

FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.

http://www.wikidata.org/entity/Q34359341

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

FDA approval summary: crizotin ...... ymphoma kinase rearrangements.

@ast

FDA approval summary: crizotin ...... ymphoma kinase rearrangements.

@en

FDA approval summary: crizotin ...... ymphoma kinase rearrangements.

@nl

type

label

FDA approval summary: crizotin ...... ymphoma kinase rearrangements.

@ast

FDA approval summary: crizotin ...... ymphoma kinase rearrangements.

@en

FDA approval summary: crizotin ...... ymphoma kinase rearrangements.

@nl

prefLabel

FDA approval summary: crizotin ...... ymphoma kinase rearrangements.

@ast

FDA approval summary: crizotin ...... ymphoma kinase rearrangements.

@en

FDA approval summary: crizotin ...... ymphoma kinase rearrangements.

@nl

P1433

Q34359341-E5EC0E3A-D83C-4EDB-A671-8D209BCF3CAC

P1476

Q34359341-7AB9CDDA-8787-4C82-BF1D-5A5C4C1CF56E

P2093

Q34359341-1BD06B18-10CF-4C91-92F5-8313912B113A

Q34359341-23333148-4E91-4C5C-8B8F-08C22EBE442C

Q34359341-5349C70E-EDBD-436D-BF21-5AE2F4D526AF

Q34359341-5BD680C1-F012-4762-B90E-73CDA5D98568

Q34359341-604EB8E6-12F0-4612-8A0B-FA1CE407DAA8

Q34359341-964BA563-7B4D-402D-AB55-D1FC6DEE3C0D

Q34359341-A2477F9B-4CAA-4298-8519-2803306FAAF6

Q34359341-D4412D2A-07F7-4855-A86F-C1EEC75824C9

P2860

Q34359341-107C0DC6-61AC-4687-A05B-2BA24355217A

Q34359341-12AA7B35-F24F-4EF8-9528-9F3200032A80

Q34359341-1C5F3387-3079-4AD1-A270-D3BAE59D3C0C

Q34359341-205C4AE2-155F-4A1E-A522-AC4F2B18E754

Q34359341-2ED89917-804E-4E2F-95F3-DF130E89E7A1

Q34359341-34C153D5-A4A5-4822-A042-B17FFCFC7EF9

Q34359341-4C966E4D-DD10-4F78-AC58-846C1B6EDB05

Q34359341-64A2EF7F-109D-4B1B-BCCC-0BFF5167CDF4

Q34359341-6CCC6B0A-353A-4C9E-BCA3-1BFAEC80C128

Q34359341-84CC46BA-FE2E-4C87-9B4E-6F58DA5AFC58

P304

Q34359341-19E60528-F410-41C1-B6D5-4DDB712C0A5C

P31

Q34359341-86EC1EDC-1B6B-4272-A1D5-2B23CD4E2258

P356

Q34359341-F15A0138-F945-4618-87D5-CD4B3EA238D0

P433

Q34359341-03D31510-DA21-402C-BC5D-117AF179E7C4

P478

Q34359341-5DC461FE-675D-4144-AFFC-7AC27B163FB0

P577

Q34359341-9DC267EC-BBB5-4375-B139-363E59AD20C5

P5875

Q34359341-97268D04-6AD1-4725-94C6-4D8B354A71C8

P698

Q34359341-5D7737F7-B899-43B6-AA5E-A5A5C4F2CA4E

P921

Q34359341-C8F2EAEA-C76E-4252-B1B0-E5BC182B42F3

P932

Q34359341-D8FD6E9C-4E78-4AEB-889C-A55E7B45C190

P356

THEONCOLOGIST.2014-0241

P1433

P1476

FDA approval summary: crizotin ...... ymphoma kinase rearrangements.

@en

P2093

Dickran Kazandjian

http://www.w3.org/2001/XMLSchema#string

Gideon M Blumenthal

http://www.w3.org/2001/XMLSchema#string

Huan-Yu Chen

http://www.w3.org/2001/XMLSchema#string

Kun He

http://www.w3.org/2001/XMLSchema#string

Mona Patel

http://www.w3.org/2001/XMLSchema#string

Patricia Keegan

http://www.w3.org/2001/XMLSchema#string

Richard Pazdur

http://www.w3.org/2001/XMLSchema#string

Robert Justice

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Cancer statistics, 2013

Cancer statistics, 2014

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

P304

e5-11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2014-0241

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265213102

http://www.w3.org/2001/XMLSchema#string

P698

25170012

http://www.w3.org/2001/XMLSchema#string

P921

P932

4201002

http://www.w3.org/2001/XMLSchema#string